Literature DB >> 26044802

Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy.

Boris Gershman1, Daniel M Moreira1, Stephen A Boorjian1, Christine M Lohse2, John C Cheville3, Brian A Costello4, Bradley C Leibovich1, R Houston Thompson5.   

Abstract

BACKGROUND: Although cytoreductive nephrectomy (CN) has been associated with perioperative morbidity, data are lacking regarding the risk of prolonged length of stay (pLOS) and delay to receipt of systemic therapy (ST).
OBJECTIVE: To evaluate the association of clinicopathologic features with postoperative complications, pLOS, and time to receipt of ST. DESIGN, SETTING, AND PARTICIPANTS: We evaluated 294 patients with M1 renal cell carcinoma treated between 1990 and 2009.
INTERVENTIONS: CN. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Logistic and Cox regressions were used to evaluate associations of clinicopathologic features with 30-d postoperative complications, pLOS (LOS ≥75th percentile), and time to receipt of ST. RESULTS AND LIMITATIONS: Fifteen (5%) patients experienced at least one Clavien grade ≥3 early complication. Among patients for whom postsurgical ST was recommended, 61% did not receive ST within 60 d, but the delay was surgery-related in only 11%. In multivariable models limited to preoperative features, liver metastases were associated with complications (odds ratio [OR] 3.73, p=0.004) and pLOS (OR 2.46, p=0.03), while a laparoscopic approach was associated with earlier administration of ST (hazard ratio [HR] 5.05, p<0.001). In multivariable models incorporating operative features, intraoperative transfusion was associated with complications (OR 1.14, p<0.001) and pLOS (OR 1.22, p<0.001), while pN1 disease was associated with pLOS (OR 2.12, p=0.049) and delay to ST (HR 0.38, p=0.004). Limitations include the retrospective design and surgical selection bias.
CONCLUSIONS: Overall, 61% of CN patients did not receive timely ST, but only 5% of patients experienced Clavien grade ≥3 complications and the delay to ST was surgery-related in 11%. Liver metastases, intraoperative transfusion, and pN1 disease were independently associated with perioperative morbidity. PATIENT
SUMMARY: We evaluated the morbidity of cytoreductive nephrectomy and identified predictors of unfavorable perioperative outcomes. Although 61% of patients did not receive timely systemic therapy, the rates of complications and surgery-related delay to systemic therapy were low.
Copyright © 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Complications; Cytoreductive nephrectomy; Prolonged hospitalization; Renal cell carcinoma; Systemic therapy

Mesh:

Substances:

Year:  2015        PMID: 26044802     DOI: 10.1016/j.eururo.2015.05.022

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  18 in total

1.  Rethinking lymph node metastasis and cytoreductive nephrectomy.

Authors:  Michael Leveridge
Journal:  Can Urol Assoc J       Date:  2016 Nov-Dec       Impact factor: 1.862

Review 2.  The Role of Nephrectomy for Kidney Cancer in the Era of Targeted and Immune Therapies.

Authors:  Ulka N Vaishampayan
Journal:  Am Soc Clin Oncol Educ Book       Date:  2016

3.  Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study.

Authors:  Nawar Hanna; Maxine Sun; Christian P Meyer; Paul L Nguyen; Sumanta K Pal; Steven L Chang; Guillermo de Velasco; Quoc-Dien Trinh; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

Review 4.  Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma.

Authors:  Walter R Hsiang; Patrick A Kenney; Michael S Leapman
Journal:  Curr Oncol Rep       Date:  2020-03-13       Impact factor: 5.075

Review 5.  Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy: a bibliographic review.

Authors:  Oscar Rodriguez Faba; Sabine D Brookman-May; Estefania Linares; Alberto Breda; Francesca Pisano; José Daniel Subiela; Francesco Sanguedolce; Maurizio Brausi; Joan Palou
Journal:  World J Urol       Date:  2017-07-12       Impact factor: 4.226

6.  Minimally invasive cytoreductive nephrectomy: a multi-institutional experience.

Authors:  Luciano Nunez Bragayrac; Jan Hoffmeyer; Daniel Abbotoy; Kristopher Attwood; Eric Kauffman; Phillipe Spiess; Andrew Wagner; Thomas Schwaab
Journal:  World J Urol       Date:  2016-04-15       Impact factor: 4.226

7.  The Impact of Increasing Hospital Volume on 90-Day Postoperative Outcomes Following Pancreaticoduodenectomy.

Authors:  Daniel J Kagedan; Nik Goyert; Qing Li; Lawrence Paszat; Alexander Kiss; Craig C Earle; Paul J Karanicolas; Alice C Wei; Nicole Mittmann; Natalie G Coburn
Journal:  J Gastrointest Surg       Date:  2017-01-05       Impact factor: 3.452

Review 8.  Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: Is There Still a Debate?

Authors:  Roser Vives Dilme; Juan Gómez Rivas; Riccardo Campi; Javier Puente; Tamara Jerez; Dmitry Enikeev; Francesco Esperto; Jesús Moreno Sierra
Journal:  Curr Urol Rep       Date:  2021-10-16       Impact factor: 3.092

Review 9.  Current Status of Minimally Invasive Surgery for Renal Cell Carcinoma.

Authors:  Zachary L Smith
Journal:  Curr Urol Rep       Date:  2016-06       Impact factor: 3.092

Review 10.  Immune checkpoint blockade in renal cell carcinoma.

Authors:  Phillip M Rappold; Andrew W Silagy; Ritesh R Kotecha; Ari A Hakimi
Journal:  J Surg Oncol       Date:  2021-03       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.